Long-term Outcomes of Patients with Crohn’s Disease Treated with Risankizumab

1. In adult patients with Crohn’s disease (CD) treated with risankizumab, only 13% of patients experienced treatment failure while 23% of patients required treatment escalation. 2. Treatment failure with risankizumab was associated with penetrating CD Evidence Rating Level: 2 (Good) Risankizumab is a newer therapeutic option approved for the management of CD, with a previous randomized clinical trial demonstrating superior efficacy compared to ustekinumab with regards to endoscopic remission at 48 weeks. However, there is a lack of data from real-world studies regarding the effectiveness of risankizumab. This retrospective cohort study therefore sought to investigate the real-world effectiveness of risankizumab in the management of CD. 106 patients (median[QR] age, 25.5[19-38] years; 50% male) from a single tertiary centre in the United States were included in this study. 13% of patients (14/106) experienced treatment failure, with penetrating CD being found during multivariate analysis to be associated with treatment failure (HR, 5.2; 95% CI, 1.6-17.2; P = .007). 23% of patients (24/106) required treatment escalation, with perianal fistulizing CD (HR, 3.3; 95% CI, 1.2-9.4; P = .023) and prior exposure to more than 2 biologics (HR, 5.8; 95% CI, 1.3-26.3; P = .022) as variables associated with treatment escalation under multivariate analysis. Overall, this study found that risankizumab is an effective treatment option in the management of CD, with few patients experiencing treatment failure. Click to read the study in IBD Image: PD